Results 71 to 80 of about 16,485 (256)

Natural killer cells in cancer immunotherapy

MedComm, Volume 5, Issue 7, July 2024.
NK cells have cytotoxic functions against tumor cells especially through NKG2D receptor. This article reviews the mechanisms how tumors escape NK‐mediated killing and therapeutic strategies with NK cells and especially MICA/B–NKG2D axis. Finally, the recent innovative CAR‐NK/NKG2D CAR‐T and MICA/B vaccines in tumor were summarized.
DanRu Wang, LingYun Dou, LiHao Sui, Yiquan Xue, Sheng Xu   +4 more
wiley   +1 more source

Revving up natural killer cells and cytokine-induced killer cells against hematological malignancies [PDF]

, 2015
Natural killer (NK) cells belong to innate immunity and exhibit cytolytic activity against infectious pathogens and tumor cells. NK-cell function is finely tuned by receptors that transduce inhibitory or activating signals, such as killer immunoglobulin ...
Alici, Alnabhan, Aversa, Bachanova, Bachanova, Bachanova, Benjamin, Benson, Benyunes, Berg, Berg, Bertaina, Betters, Biassoni, Biassoni, Bonanno, Bonanno, Braud, Burns, Burshtyn, Burshtyn, Caligiuri, Caligiuri, Campbell, Campbell, Cany, Carlens, Cheng, Cheng, Cho, Chouaib, Chu, Colonna, Conlon, Cooley, Cooley, Cosman, Curti, Denman, Durrieu, D’Andrea, Edinger, Escudier, Farag, Fehniger, Frei, Frohn, Fry, Fujisaki, Fujisaki, Garg, Gleason, Gleason, Glienke, Gong, Grimm, Gumperz, Guven, Hercend, Hontscha, Imai, Imamura, Introna, Introna, Introna, Iyengar, Jiang, Jiang, Jiang, Karlhofer, Karre, Kim, Kim, Klingemann, Klingemann, Klingemann, Knorr, Knorr, Koehl, Koehl, Koehl, Koepsell, Lang, Lapteva, Lee, Li, Li, Lim, Lim, Linn, Lister, Litwin, Liu, Ljunggren, Llano, Lotze, Lu, Luhm, Lundqvist, Lundqvist, Lundqvist, Mackall, Maus, McKenna, Meehan, Meyer-Monard, Miller, Miller, Miller, Miller, Miller, Oevermann, Olcese, Olioso, Parkhurst, Pende, Pende, Peragine, Perussia, Phillips, Phillips, Phillips, Pittari, Pittari, Rabinowich, Rettinger, Rizzieri, Romagne, Rosenberg, Rosenberg, Rosenberg, Rubnitz, Ruggeri, Rutella, Rutella, Rutella, Rutella, Schmeel, Schmidt-Wolf, Schmidt-Wolf, Schumm, Shah, Shaim, Shi, Shimasaki, Siegler, Soiffer, Somanchi, Somanchi, Spanholtz, Stern, Stroncek, Sutlu, Sweeney, Tam, Tam, Tam, Tanaka, Tomchuck, Tonn, Venstrom, Venstrom, Verneris, Vey, Vitale, Wagtmann, Wagtmann, Wiernik, Winter, Yan, Yang, Yoon, Yron, Zhang, Zhang   +174 more
core   +2 more sources

T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis [PDF]

, 2020
Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by the progressive loss of axonal myelin in several areas of the central nervous system (CNS) that is responsible for clinical symptoms such as muscle spasms, optic neuritis ...
Amormino, Carola, Frascolla, Simone, Kunkl, Martina, Tuosto, Loretta, Volpe, Elisabetta   +4 more
core   +1 more source

Cutaneous metastases: From epidemiology to therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 22, Issue 7, Page 974-993, July 2024.
Summary Cutaneous metastases are seen in up to 10% of all oncology patients and can occur in different locations depending on the entity. Cutaneous metastases are often associated with a high psychological burden and, especially in the case of exulceration, with shame and social withdrawal.
Martin Gschnell, Christian Volberg, Christina Hauser, Lisa Krönig   +3 more
wiley   +1 more source

Current progress in chimeric antigen receptor T‐cell therapy for malignant tumors

MedComm – Future Medicine, Volume 3, Issue 2, June 2024.
In recent years, chimeric antigen receptor T‐cell (CAR‐T) immunotherapy has made significant progress in the field of malignant tumor treatment, curing many patients. Here we review the mechanisms, applications, limitations, and prospects of CAR‐T treatment for hematological malignancies and solid tumors, aiming to provide direction for future research
Yashang Zheng, Jiaqian Huang, Yuhong Xu, Hui‐Yan Luo   +3 more
wiley   +1 more source

Preclinical Evaluation of a Bone-Marrow Autograft Culture Procedure for Generating Lymphokine-Activated Killer Cells in Vitro

Canadian Journal of Infectious Diseases, 1992
Despite the use of high dose chemoradiotherapy for the treatment of acute leukemia. relapse continues to be a major cause of death in patients given an autologous bone marrow transplant.
Hans-Georg Klingemann, Heather Deal, Dianne Reid, Connie J Eaves   +3 more
doaj   +1 more source

The Immune System [PDF]

, 1995
Modern biotherapy has been in use for some 30 years. The first types of biotherapy were nonspecific stimulators of the immune response, but advances in genetic engineering are allowing the mass production of pure biological products which are now being ...
Gallucci, Betty Bierut, McCarthy, Donna O.   +1 more
core   +1 more source

Reduced Cytokine Secretions by LAK Cells of Pulmonary Tuberculosis Patients in Response to Tumor Targets In Vitro [PDF]

, 2002
Activation of macrophages and other immune components to release a series of proinflammatory cytokines is one of the first events in innate resistance to intracellular infections.
Mathew, R, Narayanan, P R, Nirmala, R
core   +1 more source

Beyond muscles: Investigating immunoregulatory myokines in acute resistance exercise – A systematic review and meta‐analysis

The FASEB Journal, Volume 38, Issue 7, 15 April 2024.
This systematic review and meta‐analysis found a significant moderate positive effect of acute resistance exercise for IL‐6 and IL‐1ra and a small to moderate effect for IL‐15 and TNF‐α. For IL‐10, no significant effect was observed. Due to no data, meta‐analyses for IL‐7, TGF‐β1, and FKN could not be performed.
Miriam Ringleb, Florian Javelle, Simon Haunhorst, Wilhelm Bloch, Lena Fennen, Sabine Baumgart, Sebastian Drube, Philipp A. Reuken, Mathias W. Pletz, Heiko Wagner, Holger H. W. Gabriel, Christian Puta   +11 more
wiley   +1 more source

Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy

Clinical and Translational Medicine, Volume 14, Issue 4, April 2024.
Future PDTOs are potent models for basic research and clinical uses. Due to its editability and biobanking capability, PDTOs are powerful in vitro models for personalized drug screening, new drug discovery, and precision medicine. Abstract Background Organoid technology is an emerging and rapidly growing field that shows promise in studying organ ...
Jie Mei, Xingjian Liu, Hui‐Xiang Tian, Yixuan Chen, Yang Cao, Jun Zeng, Yung‐Chiang Liu, Yaping Chen, Yang Gao, Ji‐Ye Yin, Peng‐Yuan Wang   +10 more
wiley   +1 more source